# Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

> **NCT03751709** · PHASE1 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 22 (actual)

## Conditions studied

- B-Cell Acute Lymphoblastic Leukaemia
- ALL, Adult
- B-ALL

## Interventions

- **DRUG:** Blinatumomab
- **OTHER:** Haplo-Mismatched Cell Therapy (HMCT)

## Key facts

- **NCT ID:** NCT03751709
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-14
- **Primary completion:** 2023-03-27
- **Final completion:** 2024-11-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03751709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03751709, "Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03751709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*